Quick Answer
BPC-157 and TB-500 are both studied in tissue-remodelling research but are proposed to act through different mechanisms. BPC-157 (Body Protection Compound) is a 15-residue partial sequence of a protein found in gastric juice, studied mainly in rat gastrointestinal, tendon, ligament and muscle models. TB-500 is a synthetic peptide based on thymosin beta-4, and most of the related tissue-repair research uses the full-length protein in rodent and cell culture models. Only one published controlled study, in rats, has tested the two together, and the evidence for both is almost entirely preclinical.
BPC-157 and TB-500 are two of the most researched peptides in the tissue-remodelling category. Published work, almost all of it in rodents and cell culture, indicates both show activity in tissue-remodelling models, though they are proposed to act through different mechanisms and are studied for distinct applications.
Quick Comparison Table
| Feature | BPC-157 | TB-500 |
|---|---|---|
| Full Name | Body Protection Compound 157 | Thymosin Beta-4 (fragment) |
| Amino Acids | 15 amino acid sequence | Short fragment of the 43 amino acid thymosin beta-4 |
| Primary Research Focus | Gastrointestinal tissue, tendon/ligament models (rodent) | Actin regulation, skin wound and ligament or tendon repair (rodent, mostly full-length thymosin beta-4) |
BPC-157: Research Overview
Origin: Derived from a protective protein found in gastric juice; its developers describe it as an essential fragment of that protein, called BPC, in Sikiric et al. (1997).
Sequence: 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val), as given by Staresinic et al. (2003).
Research Mechanisms
- Studied for promotion of angiogenesis (new blood vessel formation): in chick embryo membrane and endothelial cell assays and in rat hind limb ischaemia, Hsieh et al. (2017) linked it to VEGFR2 signalling
- Studied for effects on growth-related signalling, such as increased growth hormone receptor expression in cultured rat tendon fibroblasts in Chang et al. (2014)
- Studied in relation to nitric oxide (NO) pathways, including activation of endothelial nitric oxide synthase signalling in endothelial cells (Hsieh et al., 2017)
- Researched for protective effects on gastrointestinal tissue in rat models, reviewed by its developers in Sikiric et al. (2011)
- Studied for tendon and ligament healing after surgical transection in rats, for example in Cerovecki et al. (2010)
Common Research Applications
- Tendon injury models (rat Achilles tendon)
- Ligament transection models (rat medial collateral ligament)
- Gastrointestinal lesion and fistula models (rat)
- Adjuvant arthritis, an inflammatory joint model (rat)
- Muscle injury models, such as the transected rat quadriceps in Staresinic et al. (2006)
TB-500: Research Overview
Origin: Synthetic peptide based on naturally occurring thymosin beta-4, which Rossdeutsch et al. (2008) describe as a 43 amino acid peptide. Reviews describe TB-500 as a fragment of it, for example Mendias and Awan (2026).
Sequence: analysis of a product sold as TB-500 identified the N-acetylated 17 to 23 fragment of thymosin beta-4 (Ac-LKKTETQ), seven residues long, in Esposito et al. (2012). Most of the tissue-repair research summarised below used full-length thymosin beta-4, so its findings do not automatically apply to the fragment.
Research Mechanisms
- Thymosin beta-4 binds actin monomers and blocks their polymerisation in biochemical studies, as shown by Safer et al. (1991)
- Studied for promotion of cell migration, for example of keratinocytes in culture in Malinda et al. (1999)
- Studied in relation to inflammatory signalling: it reduced NF-kB activation in cultured human corneal epithelial cells in Sosne et al. (2007)
- Researched for effects on new tissue formation in rat skin wounds, with faster re-epithelialisation, more collagen and more new blood vessels (Malinda et al., 1999)
- Studied in relation to connective tissue structure, including better organised collagen in healing rat ligament in Xu et al. (2013)
Common Research Applications
- Ligament healing after transection (rat, thymosin beta-4)
- Delayed wound healing in diabetic and aged mice; in aged mice the seven-residue actin-binding fragment promoted repair comparably to the full protein in Philp et al. (2003)
- Repaired Achilles tendon in rats, using TB-500 itself, in Biçer et al. (2026)
- Cardiac injury models (mouse, thymosin beta-4), such as Bock-Marquette et al. (2004)
Key Differences
1. Mechanism of Action
BPC-157 is studied primarily through angiogenesis and growth factor modulation, with particular research interest in the gut tissue axis.
TB-500 is studied through actin regulation, a protein essential for cell structure and movement, with particular research interest in skin wound repair and, in a few rat studies, ligament and tendon healing.
2. Research Scope
BPC-157 has a broad rodent research scope, with models ranging from tendon and gastrointestinal tissue to central nervous system injury, such as brain injury in mice in Tudor et al. (2010) and spinal cord injury in rats in Perovic et al. (2019).
Research on full-length thymosin beta-4 is also broad, from skin wounds in rats to heart injury in mice, but studies that test TB-500 itself are far fewer, and much of the PubMed literature on the name concerns anti-doping detection rather than tissue repair.
Combined Study Designs
We found one published controlled study that tests the two together. In rats with surgically repaired Achilles tendons, Biçer et al. (2026) compared BPC-157, TB-500 and the combination over four weeks. Only the TB-500 group showed a statistically significant gain in tendon load to failure, and the combination conferred no additional benefit over either peptide alone; the authors describe the work as exploratory. Administration guidance is outside the scope of research-use-only material.
Research Quality & Sourcing
When sourcing either peptide for research:
- Look for third-party lab testing (COAs)
- Verify purity
- Check for proper packaging and storage during shipping
Conclusion
Both BPC-157 and TB-500 are studied research peptides, but their tissue-remodelling evidence is almost entirely preclinical. A systematic review by Vasireddi et al. (2025) found 35 preclinical studies of BPC-157, one small retrospective clinical report and no clinical safety data, and a later review by McGuire et al. (2025) counted three small human pilot studies and no large trials. We found no published human trial of TB-500 itself, and Mendias and Awan (2026) describe rigorous human safety data for such unapproved peptides as scarce. Selection between them in a study design depends on the tissue types under investigation, the research objective, and whether a combination design is appropriate.
References
- Biçer O, et al. (2026). Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint Diseases and Related Surgery. PubMed 42542926
- Bock-Marquette I, et al. (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. PubMed 15565145
- Cerovecki T, et al. (2010). Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research. PubMed 20225319
- Chang CH, et al. (2014). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. PubMed 25415472
- Esposito S, et al. (2012). Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Testing and Analysis. PubMed 22962027
- Hsieh MJ, et al. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. PubMed 27847966
- Malinda KM, et al. (1999). Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology. PubMed 10469335
- McGuire FP, et al. (2025). Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. PubMed 40789979
- Mendias CL, Awan TM. (2026). Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine. PubMed 41966639
- Perovic D, et al. (2019). Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats. Journal of Orthopaedic Surgery and Research. PubMed 31266512
- Philp D, et al. (2003). Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair and Regeneration. PubMed 12581423
- Rossdeutsch A, et al. (2008). Thymosin beta4 and Ac-SDKP: tools to mend a broken heart. Journal of Molecular Medicine. PubMed 17701149
- Safer D, et al. (1991). Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. Journal of Biological Chemistry. PubMed 1999398
- Sikiric P, et al. (1997). Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in rats. Journal of Physiology, Paris. PubMed 9403784
- Sikiric P, et al. (2011). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. PubMed 21548867
- Sosne G, et al. (2007). Thymosin beta 4 suppression of corneal NFkappaB: a potential anti-inflammatory pathway. Experimental Eye Research. PubMed 17254567
- Staresinic M, et al. (2003). Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research. PubMed 14554208
- Staresinic M, et al. (2006). Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. Journal of Orthopaedic Research. PubMed 16609979
- Tudor M, et al. (2010). Traumatic brain injury in mice and pentadecapeptide BPC 157 effect. Regulatory Peptides. PubMed 19931318
- Vasireddi N, et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. PubMed 40756949
- Xu B, et al. (2013). Thymosin β4 enhances the healing of medial collateral ligament injury in rat. Regulatory Peptides. PubMed 23523891